Product References
mTOR inhibitor, gemcitabine and PD-L1 antibody blockade combination therapy suppresses pancreatic cancer progression via metabolic reprogramming and immune microenvironment remodeling in Trp53flox/+LSL-KrasG12D/+Pdx-1-Cre murine models.
Cancer letters
Qiu J,Feng M,Yang G,Cao Z,Liu Y,You L,Zhang T
Wed Feb 01 00:00:00 UTC 2023
PD-L1 Exon 3 Is a Hidden Switch of Its Expression and Function in Oral Cancer Cells.
International journal of molecular sciences
Yan L,Sun Y,Guo J,Jia R
Wed May 03 00:00:00 UTC 2023
Prognostic and immunotherapeutic predictive value of interleukin enhancer-binding factor 3 in hepatocellular carcinoma: Integrated bioinformatics and experimental analysis.
Gene
Qiu J,Wu X,Luo Y,Yao Y,Zhang X,Pan B,Wang X,Tang N
Fri Mar 10 00:00:00 UTC 2023
LRPPRC facilitates tumor progression and immune evasion through upregulation of m6A modification of PD-L1 mRNA in hepatocellular carcinoma.
Frontiers in immunology
Wang H,Tang A,Cui Y,Gong H,Li H
Tue Apr 18 00:00:00 UTC 2023
LRPPRC facilitates tumor progression and immune evasion through upregulation of m6A modification of PD-L1 mRNA in hepatocellular carcinoma.
Frontiers in immunology
Wang H,Tang A,Cui Y,Gong H,Li H
Tue Apr 18 00:00:00 UTC 2023
LRPPRC facilitates tumor progression and immune evasion through upregulation of m6A modification of PD-L1 mRNA in hepatocellular carcinoma.
Frontiers in immunology
Wang H,Tang A,Cui Y,Gong H,Li H
Tue Apr 18 00:00:00 UTC 2023
LRPPRC facilitates tumor progression and immune evasion through upregulation of m6A modification of PD-L1 mRNA in hepatocellular carcinoma.
Frontiers in immunology
Wang H,Tang A,Cui Y,Gong H,Li H
Tue Apr 18 00:00:00 UTC 2023
LRPPRC facilitates tumor progression and immune evasion through upregulation of m6A modification of PD-L1 mRNA in hepatocellular carcinoma.
Frontiers in immunology
Wang H,Tang A,Cui Y,Gong H,Li H
Tue Apr 18 00:00:00 UTC 2023
LRPPRC facilitates tumor progression and immune evasion through upregulation of m6A modification of PD-L1 mRNA in hepatocellular carcinoma.
Frontiers in immunology
Wang H,Tang A,Cui Y,Gong H,Li H
Tue Apr 18 00:00:00 UTC 2023
Epigenetically regulated lncRNAs dissect the intratumoural heterogeneity and facilitate immune evasion of glioblastomas.
Theranostics
Xu D,Cao M,Wang B,Bi X,Zhang H,Wu D,Zhang C,Xu J,Xu Z,Zheng D,Chen L,Li P,Wang H,Liu Y,Jiang H,Li K
Mon Apr 17 00:00:00 UTC 2023
Machine learning-based identification of tumor-infiltrating immune cell-associated model with appealing implications in improving prognosis and immunotherapy response in bladder cancer patients.
Frontiers in immunology
Chen H,Yang W,Ji Z
Tue Apr 18 00:00:00 UTC 2023
m6A reader YTHDF3 is associated with clinical prognosis, related RNA signatures and immunosuppression in gastric cancer.
Cellular signalling
Yu Y,Meng LL,Chen XY,Fan HN,Chen M,Zhang J,Zhu JS
Tue Aug 01 00:00:00 UTC 2023
m6A reader YTHDF3 is associated with clinical prognosis, related RNA signatures and immunosuppression in gastric cancer.
Cellular signalling
Yu Y,Meng LL,Chen XY,Fan HN,Chen M,Zhang J,Zhu JS
Tue Aug 01 00:00:00 UTC 2023
Overexpression of DBT suppresses the aggressiveness of renal clear cell carcinoma and correlates with immune infiltration.
Frontiers in immunology
Zhang C,Huang G,Yang J,Jiang Y,Huang R,Ye Z,Huang Y,Hu H,Xi X
Wed Jul 05 00:00:00 UTC 2023
SHFM1 deficiency suppresses esophageal squamous cell carcinomas progression via modulating NF‑κB signaling and enhancing nature killer cell‑mediated tumor surveillance.
Experimental and therapeutic medicine
Wu Y,Wang Z,Li S,Chen X,Zhou S
Mon May 01 00:00:00 UTC 2023
Increased OIT3 in macrophages promotes PD-L1 expression and hepatocellular carcinogenesis via NF-κB signaling.
Experimental cell research
Wen J,Yang S,Yan G,Lei J,Liu X,Zhang N,Zhang J,Deng H,Wu L,Li Y
Sat Jul 15 00:00:00 UTC 2023
Chang Wei Qing Decoction enhances the anti-tumor effect of PD-1 inhibitor therapy by regulating the immune microenvironment and gut microbiota in colorectal cancer.
Chinese journal of natural medicines
Wang T,Wu L,Wang S,Shi X,Liu H,Deng W
Mon May 01 00:00:00 UTC 2023
Chang Wei Qing Decoction enhances the anti-tumor effect of PD-1 inhibitor therapy by regulating the immune microenvironment and gut microbiota in colorectal cancer.
Chinese journal of natural medicines
Wang T,Wu L,Wang S,Shi X,Liu H,Deng W
Mon May 01 00:00:00 UTC 2023
Chang Wei Qing Decoction enhances the anti-tumor effect of PD-1 inhibitor therapy by regulating the immune microenvironment and gut microbiota in colorectal cancer.
Chinese journal of natural medicines
Wang T,Wu L,Wang S,Shi X,Liu H,Deng W
Mon May 01 00:00:00 UTC 2023
Chang Wei Qing Decoction enhances the anti-tumor effect of PD-1 inhibitor therapy by regulating the immune microenvironment and gut microbiota in colorectal cancer.
Chinese journal of natural medicines
Wang T,Wu L,Wang S,Shi X,Liu H,Deng W
Mon May 01 00:00:00 UTC 2023
Chang Wei Qing Decoction enhances the anti-tumor effect of PD-1 inhibitor therapy by regulating the immune microenvironment and gut microbiota in colorectal cancer.
Chinese journal of natural medicines
Wang T,Wu L,Wang S,Shi X,Liu H,Deng W
Mon May 01 00:00:00 UTC 2023
Chang Wei Qing Decoction enhances the anti-tumor effect of PD-1 inhibitor therapy by regulating the immune microenvironment and gut microbiota in colorectal cancer.
Chinese journal of natural medicines
Wang T,Wu L,Wang S,Shi X,Liu H,Deng W
Mon May 01 00:00:00 UTC 2023
Electroacupuncture Alleviates CFA-Induced Inflammatory Pain via PD-L1/PD-1-SHP-1 Pathway.
Molecular neurobiology
Deng D,Xu F,Ma L,Zhang T,Wang Y,Huang S,Zhao W,Chen X
Mon May 01 00:00:00 UTC 2023
Electroacupuncture Alleviates CFA-Induced Inflammatory Pain via PD-L1/PD-1-SHP-1 Pathway.
Molecular neurobiology
Deng D,Xu F,Ma L,Zhang T,Wang Y,Huang S,Zhao W,Chen X
Mon May 01 00:00:00 UTC 2023
Afatinib combined with anti-PD1 enhances immunotherapy of hepatocellular carcinoma via ERBB2/STAT3/PD-L1 signaling.
Frontiers in oncology
Yu C,Zhang X,Wang M,Xu G,Zhao S,Feng Y,Pan C,Yang W,Zhou J,Shang L,Ma Y
Mon Jun 19 00:00:00 UTC 2023
Sensitive and quantitative in vivo analysis of PD-L1 using magnetic particle imaging and imaging-guided immunotherapy.
European journal of nuclear medicine and molecular imaging
Peng Z,Lu C,Shi G,Yin L,Liang X,Song G,Tian J,Du Y
Sat Apr 01 00:00:00 UTC 2023
Sensitive and quantitative in vivo analysis of PD-L1 using magnetic particle imaging and imaging-guided immunotherapy.
European journal of nuclear medicine and molecular imaging
Peng Z,Lu C,Shi G,Yin L,Liang X,Song G,Tian J,Du Y
Sat Apr 01 00:00:00 UTC 2023
Allosteric Regulation of IGF2BP1 as a Novel Strategy for the Activation of Tumor Immune Microenvironment.
ACS central science
Liu Y,Guo Q,Yang H,Zhang XW,Feng N,Wang JK,Liu TT,Zeng KW,Tu PF
Wed Aug 24 00:00:00 UTC 2022
BMSCs improve TNBS-induced colitis in rats by inducing Treg differentiation by expressing PD-L1.
Biotechnology letters
Gao F,Cui D,Zuo D,Shou Z,Yang J,Yu T,Liu Y,Chu S,Zhu F,Wei C
Tue Nov 01 00:00:00 UTC 2022
Multimodal Imaging Response after the Singular or Combination Treatments of Vascular Endothelial Growth Factor Inhibitor and Immune Checkpoint Inhibitor.
Molecular pharmaceutics
Ren Y,Pan F,Kan X,Wang J,Han P,Yan J,Li L,Sun P,Liu CY,Bao Q,Yang L,Zheng C
Mon Oct 03 00:00:00 UTC 2022
Bacteria-mediated metformin-loaded peptide hydrogel reprograms the tumor immune microenvironment in glioblastoma.
Biomaterials
Zhu L,Liu J,Qiu M,Chen J,Liang Q,Peng G,Zou Z
Thu Sep 01 00:00:00 UTC 2022
Cancer-cell-biomimetic nanoparticles systemically eliminate hypoxia tumors by synergistic chemotherapy and checkpoint blockade immunotherapy.
Acta pharmaceutica Sinica. B
Yao Y,Chen H,Tan N
Fri Apr 01 00:00:00 UTC 2022
The role of YAP1 in survival prediction, immune modulation, and drug response: A pan-cancer perspective.
Frontiers in immunology
Hu X,Zhang Y,Yu H,Zhao Y,Sun X,Li Q,Wang Y
Thu Dec 15 00:00:00 UTC 2022
Comprehensive analysis of N6-methyladenosine regulators with the tumor immune landscape and correlation between the insulin-like growth factor 2 mRNA-binding protein 3 and programmed death ligand 1 in bladder cancer.
Cancer cell international
Cui J,Zhu Y,Liu X,Wang W,Jiang X,Xia Y,Zhou G,Chen S,Shi B
Fri Feb 11 00:00:00 UTC 2022
A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression.
Journal of experimental & clinical cancer research : CR
Liu W,Ren D,Xiong W,Jin X,Zhu L
Wed Jan 26 00:00:00 UTC 2022
A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression.
Journal of experimental & clinical cancer research : CR
Liu W,Ren D,Xiong W,Jin X,Zhu L
Wed Jan 26 00:00:00 UTC 2022
Immunotherapy landscape analyses of necroptosis characteristics for breast cancer patients.
Journal of translational medicine
Yu H,Lv W,Tan Y,He X,Wu Y,Wu M,Zhang Q
Thu Jul 21 00:00:00 UTC 2022
MicroRNA-20a promotes non-small cell lung cancer proliferation by upregulating PD-L1 by targeting PTEN.
Oncology letters
Gong J,Shen Y,Jiang F,Wang Y,Chu L,Sun J,Shen P,Chen M
Sun May 01 00:00:00 UTC 2022
Gasdermin D restricts anti-tumor immunity during PD-L1 checkpoint blockade.
Cell reports
Jiang Y,Yang Y,Hu Y,Yang R,Huang J,Liu Y,Wu Y,Li S,Ma C,Humphries F,Wang B,Wang X,Hu Z,Yang S
Tue Oct 25 00:00:00 UTC 2022
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 1: Focus on Immunohistochemical Results with Discussion of Pre-Analytical and Interpretation Variables.
Cells
Palicelli A,Bonacini M,Croci S,Magi-Galluzzi C,Cañete-Portillo S,Chaux A,Bisagni A,Zanetti E,De Biase D,Melli B,Sanguedolce F,Ragazzi M,Bonasoni MP,Soriano A,Ascani S,Zizzo M,Castro Ruiz C,De Leo A,Giordano G,Landriscina M,Carrieri G,Cormio L,Berney DM,Athanazio D,Gandhi J,Cavazza A,Santandrea G,Tafuni A,Zanelli M
Sun Nov 14 00:00:00 UTC 2021
A hybrid membrane coating nanodrug system against gastric cancer via the VEGFR2/STAT3 signaling pathway.
Journal of materials chemistry. B
Long Y,Wang Z,Fan J,Yuan L,Tong C,Zhao Y,Liu B
Wed May 12 00:00:00 UTC 2021
A hybrid membrane coating nanodrug system against gastric cancer via the VEGFR2/STAT3 signaling pathway.
Journal of materials chemistry. B
Long Y,Wang Z,Fan J,Yuan L,Tong C,Zhao Y,Liu B
Wed May 12 00:00:00 UTC 2021
A hybrid membrane coating nanodrug system against gastric cancer via the VEGFR2/STAT3 signaling pathway.
Journal of materials chemistry. B
Long Y,Wang Z,Fan J,Yuan L,Tong C,Zhao Y,Liu B
Wed May 12 00:00:00 UTC 2021
A hybrid membrane coating nanodrug system against gastric cancer via the VEGFR2/STAT3 signaling pathway.
Journal of materials chemistry. B
Long Y,Wang Z,Fan J,Yuan L,Tong C,Zhao Y,Liu B
Wed May 12 00:00:00 UTC 2021
IFNγ/PD-L1 Signaling Improves the Responsiveness of Anti-PD-1 Therapy in Colorectal Cancer: An in vitro Study.
OncoTargets and therapy
Yuan W,Deng D,Li H,Hu X,Shang X,Hou X,Jiang H,He H
Sat Apr 23 00:00:00 UTC 2022
Berry anthocyanidins inhibit intestinal polyps and colon tumors by modulation of Src, EGFR and the colon inflammatory environment.
Oncoscience
Mudd AM,Gu T,Munagala R,Jeyabalan J,Fraig M,Egilmez NK,Gupta RC
Tue Dec 21 00:00:00 UTC 2021
c-Myb facilitates immune escape of esophageal adenocarcinoma cells through the miR-145-5p/SPOP/PD-L1 axis.
Clinical and translational medicine
Zhang L,Wang X,Li Y,Han J,Gao X,Li S,Wang F
Wed Sep 01 00:00:00 UTC 2021
c-Myb facilitates immune escape of esophageal adenocarcinoma cells through the miR-145-5p/SPOP/PD-L1 axis.
Clinical and translational medicine
Zhang L,Wang X,Li Y,Han J,Gao X,Li S,Wang F
Wed Sep 01 00:00:00 UTC 2021
c-Myb facilitates immune escape of esophageal adenocarcinoma cells through the miR-145-5p/SPOP/PD-L1 axis.
Clinical and translational medicine
Zhang L,Wang X,Li Y,Han J,Gao X,Li S,Wang F
Wed Sep 01 00:00:00 UTC 2021
c-Myb facilitates immune escape of esophageal adenocarcinoma cells through the miR-145-5p/SPOP/PD-L1 axis.
Clinical and translational medicine
Zhang L,Wang X,Li Y,Han J,Gao X,Li S,Wang F
Wed Sep 01 00:00:00 UTC 2021
Doxorubicin and PD-L1 siRNA co-delivery with stem cell membrane-coated polydopamine nanoparticles for the targeted chemoimmunotherapy of PCa bone metastases.
Nanoscale
Mu X,Zhang M,Wei A,Yin F,Wang Y,Hu K,Jiang J
Fri May 21 00:00:00 UTC 2021
An update of knowledge on PD-L1 in head and neck cancers: Physiologic, prognostic and therapeutic perspectives.
Oral diseases
Lenouvel D,González-Moles MÁ,Talbaoui A,Ramos-García P,González-Ruiz L,Ruiz-Ávila I,Gil-Montoya JA
Wed Apr 01 00:00:00 UTC 2020
Identification and validation of a combined hypoxia and immune index for triple-negative breast cancer.
Molecular oncology
Zheng S,Zou Y,Liang JY,Xiao W,Yang A,Meng T,Lu S,Luo Z,Xie X
Sun Nov 01 00:00:00 UTC 2020
Tumor-associated macrophages induce PD-L1 expression in gastric cancer cells through IL-6 and TNF-α signaling.
Experimental cell research
Ju X,Zhang H,Zhou Z,Chen M,Wang Q
Sun Nov 15 00:00:00 UTC 2020
Tumor-associated macrophages induce PD-L1 expression in gastric cancer cells through IL-6 and TNF-α signaling.
Experimental cell research
Ju X,Zhang H,Zhou Z,Chen M,Wang Q
Sun Nov 15 00:00:00 UTC 2020
Promoting the activation of T cells with glycopolymer-modified dendritic cells by enhancing cell interactions.
Science advances
Yu L,Feng R,Zhu L,Hao Q,Chu J,Gu Y,Luo Y,Zhang Z,Chen G,Chen H
Sun Nov 01 00:00:00 UTC 2020
Anti-PD-1 antibody combined with chemotherapy suppresses the growth of mesothelioma by reducing myeloid-derived suppressor cells.
Lung cancer (Amsterdam, Netherlands)
Otsuka K,Mitsuhashi A,Goto H,Hanibuchi M,Koyama K,Ogawa H,Ogino H,Saijo A,Kozai H,Yoneda H,Tobiume M,Kishuku M,Ishizawa K,Nishioka Y
Sat Aug 01 00:00:00 UTC 2020
New insight on the correlation of metabolic status on 18F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer.
European journal of nuclear medicine and molecular imaging
Wang Y,Zhao N,Wu Z,Pan N,Shen X,Liu T,Wei F,You J,Xu W,Ren X
Fri May 01 00:00:00 UTC 2020
Changes in Tumor-Infiltrating Lymphocytes and Vascular Normalization in Breast Cancer Patients After Neoadjuvant Chemotherapy and Their Correlations With DFS.
Frontiers in oncology
Wang Q,Xiang Q,Yu L,Hu T,Chen Y,Wang J,Nie X,Cheng J
Thu Mar 18 00:00:00 UTC 2021
All-trans retinoic acid induces anti-tumor effects via STAT3 signaling inhibition in oral squamous cell carcinoma and oral dysplasia.
Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
Chen XJ,He MJ,Zhou G
Tue Oct 01 00:00:00 UTC 2019
Retinoic Acid-Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer.
Cancer research
Cao D,Qi Z,Pang Y,Li H,Xie H,Wu J,Huang Y,Zhu Y,Shen Y,Zhu Y,Dai B,Hu X,Ye D,Wang Z
Wed May 15 00:00:00 UTC 2019
Hyperresponsiveness to interferon gamma exposure as a response mechanism to anti-PD-1 therapy in microsatellite instability colorectal cancer.
Cancer immunology, immunotherapy : CII
Yuan W,Deng D,Jiang H,Tu C,Shang X,He H,Niu R,Dong J
Fri Feb 01 00:00:00 UTC 2019
Hyperresponsiveness to interferon gamma exposure as a response mechanism to anti-PD-1 therapy in microsatellite instability colorectal cancer.
Cancer immunology, immunotherapy : CII
Yuan W,Deng D,Jiang H,Tu C,Shang X,He H,Niu R,Dong J
Fri Feb 01 00:00:00 UTC 2019
PD-L1 regulates tumorigenesis and autophagy of ovarian cancer by activating mTORC signaling.
Bioscience reports
Gao H,Zhang J,Ren X
Fri Dec 20 00:00:00 UTC 2019
PD-1 Blockade Following Isolated Limb Perfusion with Vaccinia Virus Prevents Local and Distant Relapse of Soft-tissue Sarcoma.
Clinical cancer research : an official journal of the American Association for Cancer Research
Smith HG,Mansfield D,Roulstone V,Kyula-Currie JN,McLaughlin M,Patel RR,Bergerhoff KF,Paget JT,Dillon MT,Khan A,Melcher A,Thway K,Harrington KJ,Hayes AJ
Sat Jun 01 00:00:00 UTC 2019
DCUN1D1 facilitates tumor metastasis by activating FAK signaling and up-regulates PD-L1 in non-small-cell lung cancer.
Experimental cell research
Li J,Yu T,Yan M,Zhang X,Liao L,Zhu M,Lin H,Pan H,Yao M
Tue Jan 15 00:00:00 UTC 2019
Verteporfin suppresses the proliferation, epithelial-mesenchymal transition and stemness of head and neck squamous carcinoma cells via inhibiting YAP1.
Journal of Cancer
Liu K,Du S,Gao P,Zheng J
Thu Oct 01 00:00:00 UTC 2020
The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
Oral oncology
Yang WF,Wong MCM,Thomson PJ,Li KY,Su YX
Thu Nov 01 00:00:00 UTC 2018
Programmed death-ligand 1 (PD-L1) expression in pleomorphic carcinoma of the lung.
Journal of surgical oncology
Imanishi N,Hirai A,Yoneda K,Shimajiri S,Kuwata T,Tashima Y,Takeuchi M,Iwai Y,Ichiki Y,Tanaka F
Fri Jun 01 00:00:00 UTC 2018
The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma.
Lung cancer (Amsterdam, Netherlands)
Takada K,Okamoto T,Toyokawa G,Kozuma Y,Matsubara T,Haratake N,Akamine T,Takamori S,Katsura M,Shoji F,Oda Y,Maehara Y
Wed Feb 01 00:00:00 UTC 2017
Associations among pretreatment tumor necrosis and the expression of HIF-1α and PD-L1 in advanced oral squamous cell carcinoma and the prognostic impact thereof.
Oral oncology
Chen TC,Wu CT,Wang CP,Hsu WL,Yang TL,Lou PJ,Ko JY,Chang YL
Sun Nov 01 00:00:00 UTC 2015
